Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
LOS ANGELES, March 18, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Natus Medical Incorporated (“Natus” or the “Company”) (Nasdaq:BABY). Investors who purchased or otherwise acquired Natus shares between October 16, 2015 and April 3, 2016 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 31, 2016 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, during the Class Period, Natus released materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects, including that: the government of Venezuela was unable to spend tens of millions of dollars in prepayments to Natus, needed in October 2015; that Natus did not have the capacity to effectively enforce its rights under its supply contract; Natus’ revenues related to the supply contract were dependent on the results of Venezuelan elections; and as therefore, Natus could not actually achieve the increased guidance offered by Defendants, which lacked a reasonable basis.
When this information was revealed to the public, the value of Natus Medical Incorporated stock declined, causing investors harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
